Nonmotor symptoms in parkinson's disease. Expanding the view of parkinson's disease beyond a pure motor, pure dopaminergic problem

Neurologic Clinics

Volumn 31, Issue 3 S, 2013, Pages

  Sung, Victor W ^a   Nicholas, Anthony P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dopaminergic; Motor symptoms; Nonmotor symptoms; Parkinson's disease

Indexed keywords

CLOZAPINE; DESIPRAMINE; DOPAMINE; MACROGOL; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PRAMIPEXOLE; RIVASTIGMINE;

ANHEDONIA; ANXIETY DISORDER; APATHY; ARTHRALGIA; AUTONOMIC DYSFUNCTION; BRADYPHRENIA; COGNITIVE DEFECT; CONSTIPATION; DAYTIME SOMNOLENCE; DELUSION; DEMENTIA; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DYSAUTONOMIA; DYSPNEA; EVIDENCE BASED PRACTICE; FATIGUE; FECES INCONTINENCE; HUMAN; HYPERSALIVATION; HYPOTENSION; ILLUSION; IMPULSE CONTROL DISORDER; INSOMNIA; LIMB PAIN; MOOD DISORDER; NONMOTOR SYMPTOM; ORTHOSTATIC HYPOTENSION; PANIC; PARASOMNIA; PARESTHESIA; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIODIC LIMB MOVEMENT DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYMPTOM; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VISCERAL PAIN; VISUAL HALLUCINATION;

DOPAMINERGIC; MOTOR SYMPTOMS; NONMOTOR SYMPTOMS; PARKINSON'S DISEASE;

ANIMALS; COGNITION DISORDERS; DOPAMINE; DOPAMINE AGENTS; HUMANS; MENTAL DISORDERS; PARKINSON DISEASE; QUALITY OF LIFE; SLEEP DISORDERS;

EID: 84881496533     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.04.013     Document Type: Review

References (78)

1. Parkinson J. An essay on the shaking palsy 1817, Whittingham and Rowland, London.
2. Pahwa R., Factor S.A., Lyons K.E., et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
3. Schapira A., Olanow W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 2008, 46(Suppl 2):S47-S55.
4. Chaudhuri K., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
5. Chaudhuri K.R., Yates L., Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005, 5:275-283.
6. Shulman L.M., Taback R.L., Bean J., et al. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001, 16:507-510.
7. Simuni T., Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol 2008, 64(Suppl 2):S65-S80.
8. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002, 59:408-413.
9. Wolters E. Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:S6-S12.
10. Zeimssen T., Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:323-332.
11. Zesiewicz T.A., Sullivan K.L., Arnulf I., et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010, 74:924-931.
12. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26(3):399-406.
13. Hwynn N., Haq I.U., Malaty I.A., et al. The frequency of nonmotor symptoms among advanced Parkinson patients may depend on instrument used for assessment. Parkinsons Dis 2011, 2011:290195.
14. Hwynn N., Ul Haq I., Malaty I.A., et al. Effect of deep brain stimulation on Parkinson's nonmotor symptoms following unilateral DBS: a pilot study. Parkinsons Dis 2011, 2011:507416.
15. van der Hoek T.C., Bus B.A., Matui P., et al. Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender. JNeurol Sci 2011, 310(1-2):220-224.
16. Martignoni E., Pacchetti C., Godi L., et al. Autonomic disorders in Parkinson's disease. JNeural Transm Suppl 1995, 45:11-19.
17. Martinez-Martin P., Schapira A.H., Stocchi F., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22(11):1623-1629.
18. Campos-Sousa R.N., Quagliato E., da Silva B.B., et al. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 2003, 61(2B):359-363.
19. Sakakibara R., Shinotoh H., Uchiyama T., et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001, 92(1-2):76-85.
20. Yu M., Roane D.M., Miner C.R., et al. Dimensions of sexual dysfunction in Parkinson disease. Am J Geriatr Psychiatry 2004, 12(2):221-226.
21. Truong D.D., Bhidayasiri R., Wolters E. Management of non-motor symptoms in advanced Parkinson disease. JNeurol Sci 2008, 266(1-2):216-228.
22. Ha A.D., Brown C.H., York M.K., et al. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord 2011, 17(8):625-628.
23. Shulman L.M., Taback R.L., Rabinstein A.A., et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002, 8:193-197.
24. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106(Pt 2):257-270.
25. Stocchi F., Barbato L., Nordera G., et al. Sleep disorders in Parkinson's disease. JNeurol 1998, 245(Suppl 1):S15-S18.
26. Tandberg E., Larsen J.P., Karlsen K. Acommunity-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998, 13(6):895-899.
27. McCarter S.J., St Louis E.K., Boeve B.F. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep 2012, 12(2):182-192.
28. Postuma R.B., Aarsland D., Barone P., et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012, 27(5):617-626.
29. Postuma R.B., Lang A.E., Gagnon J.F., et al. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012, 135(Pt 6):1860-1870.
30. Gallagher D.A., Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012, 46(3):581-589.
31. Walsh K., Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001, 77(904):89-93.
32. Lemke M.R., Fuchs G., Gemende I., et al. Depression and Parkinson's disease. JNeurol 2004, 251(Suppl 6). VI/24-27.
33. Vilas D., Pont-Sunyer C., Tolosa E. Impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):S80-S84.
34. Goetz C.G. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol 1999, 80:419-423.
35. Chaudhuri K.R., Prieto-Jurcynska C., Naidu Y., et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010, 25(6):704-709.
36. Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. JNeural Transm 2010, 117(7):837-846.
37. Stocchi F., Jenner P., Obeso J.A. When do levodopa motor fluctuations first appear in Parkinson's disease?. Eur Neurol 2010, 63(5):257-266.
38. Alvord E.C.J. The pathology of parkinsonism. Pathology of the nervous system 1968, vol. 1:1152-1161. McGraw-Hill, New York.
39. Forno L.S. Pathology of parkinsonism. JNeurosurg 1966, 24(Suppl 2):266-271.
40. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960, 24:1236-1239. [in German].
41. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
42. Braak H., de Vos R.A., Bohl J., et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
43. Phillips R.J., Walter G.C., Wilder S.L., et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?. Neuroscience 2008, 153:733-750.
44. Wakabayashi K., Takahashi H., Takeda S., et al. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988, 76:217-221.
45. D'Amato R.J., Zweig R.M., Whitehouse P.J., et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987, 22:229-236.
46. Greenfield J.G., Bosanquet F.D. The brain-stem lesions in parkinsonism. JNeurol Neurosurg Psychiatr 1953, 16:213-226.
47. Saper C.B., Sorrentino D.M., German D.C., et al. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 1991, 29:577-584.
48. Gradin K., Nicholas A.P., Hjemdahl P., et al. Contrasting cardiovascular responses from intrathecal administration of epinephrine and norepinephrine in conscious rats: role of α1- and α2-adrenoceptors. JCardiovasc Pharmacol 1992, 20:367-374.
49. Grinberg L.T., Rueb U., Alho A.T., et al. Brainstem pathology and non-motor symptoms in PD. JNeurol Sci 2010, 289(1-2):81-88.
50. Bernheimer H., Birkmayer W., Hornykiewicz O. Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin Wschr 1961, 39:1056-1059. [in German].
51. Rye D.B. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 2004, 63(8 Suppl 3):S2-S7.
52. Rye D.B., Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002, 58(3):341-346.
53. Braak H., Rub U., Jansen Steur E.N., et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005, 64(8):1404-1410.
54. Arai R., Karasawa N., Geffard M., et al. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995, 195:195-198.
55. Arai R., Karasawa N., Geffard M., et al. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 1994, 667:295-299.
56. Carta M., Carlsson T., Kirik D., et al. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
57. Everett G., Borcherding J.W. L-Dopa: effect on the concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970, 168:849-850.
58. Ng K.Y., Chase T.N., Colburn R.W., et al. L-Dopa-induced release of cerebral monoamines. Science 1970, 170:76-77.
59. Nicholas A.P., Buck K., Ferger B. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Neurosci Lett 2008, 443:204-208.
60. Rommelfanger K.S., Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 2007, 74:177-190.
61. Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res 1990, 523:134-138.
62. Nicholas A.P., Pieribone V.A., Hökfelt T. Distribution of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. JComp Neurol 1993, 328:575-594.
63. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
64. Cheng E.M., Tonn S., Swain-Eng R., et al. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2010, 75(22):2021-2027.
65. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005, 20:726-733.
66. Chaudhuri K.R., Martinez-Martin P., Schapira A.H., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21(7):916-923.
67. Romenets S.R., Wolfson C., Galatas C., et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord 2012, 18(1):54-58.
68. Chaudhuri K.R., Martinez-Martin P., Brown R.G., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22(13):1901-1911.
69. Martinez-Martin P., Rodriguez-Blazquez C., Abe K., et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009, 73(19):1584-1591.
70. Martinez-Martin P., Jeukens-Visser M., Lyons K.E., et al. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord 2011, 26(13):2371-2380.
71. Marinus J., Visser M., Stiggelbout A.M., et al. Ashort scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. JNeurol Neurosurg Psychiatr 2004, 75(3):388-395.
72. Evatt M.L., Chaudhuri K.R., Chou K.L., et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009, 24(5):635-646.
73. Hogl B., Arnulf I., Comella C., et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010, 25(16):2704-2716.
74. Kulisevsky J., Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009, 24(8):1103-1110.
75. Schrag A., Barone P., Brown R.G., et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007, 22(8):1077-1092.
76. Tolosa E., Pont-Sunyer C. Progress in defining the premotor phase of Parkinson's disease. JNeurol Sci 2011, 310(1-2):4-8.
77. Seppi K., Weintraub D., Coelho M., et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26(Suppl 3):S42-S80.
78. Wood L.D., Neumiller J.J., Setter S.M., et al. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother 2010, 8:294-315.